Literature DB >> 35986791

Evaluation of IL-23p19/Ebi3 (IL-39) gingival crevicular fluid levels in periodontal health, gingivitis, and periodontitis.

Aysegul Sari1,2, Serdar Dogan3, Luigi Nibali4, Serhat Koseoglu5.   

Abstract

OBJECTIVES: IL-23p19/Ebi3 (IL-39) was described as a new IL-12 family member. The aim of this study is to evaluate the gingival crevicular fluid (GCF) IL-39 levels in periodontal diseases and health and to correlate them to GCF levels of IL-1β and periostin.
MATERIALS AND METHODS: Sixty-six adult patients were included in the study. The study design was comprised of three groups, each containing 22 individuals: the periodontally healthy (PH), gingivitis (G), and periodontitis (P) groups. The clinical periodontal parameters were recorded and GCF samples were collected from the participants. GCF interleukin (IL)-39, IL-1β, and periostin levels were examined using the enzyme-linked immunosorbent assay.
RESULTS: GCF IL‑1β, periostin, and IL-39 levels were higher in the P and G groups than in the PH group (p < 0.001). Positive correlations were detected between all GCF biochemical parameters and clinical periodontal parameters (p < 0.05). In the multivariate generalized linear regression analysis, the P (β = 37.6, 95% CI = 22.9-52.4) and G (β = 28.4, 95% CI = 15.8-41) groups were associated with GCF IL-39 levels (p < 0.001).
CONCLUSION: IL-39 levels were elevated in the presence of periodontal disease paralleling the increase in IL‑1β and periostin levels. IL-39 may have a role in the periodontal inflammation process. STATEMENT OF CLINICAL RELEVANCE: IL-39, a new cytokine from the IL-12 family, can be a possible predictor marker of periodontal diseases.
© 2022. The Author(s).

Entities:  

Keywords:  Cytokine; IL-23p19/Ebi3 (IL-39); Inflammation; Periodontal disease; Periodontitis

Year:  2022        PMID: 35986791     DOI: 10.1007/s00784-022-04681-w

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.606


  59 in total

Review 1.  Inflammatory mediators and the destruction of bone.

Authors:  G R Mundy
Journal:  J Periodontal Res       Date:  1991-05       Impact factor: 4.419

Review 2.  Mechanisms of alveolar bone destruction in periodontitis.

Authors:  Z Schwartz; J Goultschin; D D Dean; B D Boyan
Journal:  Periodontol 2000       Date:  1997-06       Impact factor: 7.589

Review 3.  Periostin in Bone Regeneration.

Authors:  Oriane Duchamp de Lageneste; Céline Colnot
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 4.  Functions of Periostin in dental tissues and its role in periodontal tissues' regeneration.

Authors:  Juan Du; Minqi Li
Journal:  Cell Mol Life Sci       Date:  2017-09-09       Impact factor: 9.261

Review 5.  Pro-resolving mediators in the regulation of periodontal disease.

Authors:  Thomas E Van Dyke
Journal:  Mol Aspects Med       Date:  2017-05-18

6.  Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta.

Authors:  K Horiuchi; N Amizuka; S Takeshita; H Takamatsu; M Katsuura; H Ozawa; Y Toyama; L F Bonewald; A Kudo
Journal:  J Bone Miner Res       Date:  1999-07       Impact factor: 6.741

Review 7.  Dendritic cells a critical link to alveolar bone loss and systemic disease risk in periodontitis: Immunotherapeutic implications.

Authors:  Ahmed R El-Awady; Mahmoud Elashiry; Ana C Morandini; Mohamed M Meghil; Christopher W Cutler
Journal:  Periodontol 2000       Date:  2022-03-04       Impact factor: 12.239

Review 8.  Microbial signatures of health, gingivitis, and periodontitis.

Authors:  Loreto Abusleme; Anilei Hoare; Bo-Young Hong; Patricia I Diaz
Journal:  Periodontol 2000       Date:  2021-03-10       Impact factor: 7.589

Review 9.  Polymicrobial communities in periodontal disease: Their quasi-organismal nature and dialogue with the host.

Authors:  George Hajishengallis; Richard J Lamont
Journal:  Periodontol 2000       Date:  2021-03-10       Impact factor: 12.239

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.